Fleury S.A. (BVMF:FLRY3)

Market Cap	8.25B +18.7%
Revenue (ttm)	8.50B +9.0%
Net Income	634.76M +1.2%
EPS	1.16 +1.3%
Shares Out	543.62M
PE Ratio	13.03
Forward PE	11.13
Dividend	1.21 (7.97%)
Ex-Dividend Date	n/a

Volume	1,391,800
Open	15.00
Previous Close	15.16
Day's Range	14.95 - 15.32
52-Week Range	12.48 - 18.10
Beta	0.28
Analysts	Buy
Price Target	17.50 (+15.28%)
Earnings Date	Aug 6, 2026

About Fleury

Fleury S.A., together with its subsidiaries, provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides health management services, such as telemedicine; orthopedic medicine services; laboratory support; toxicological exam; preventive, integrated solutions, and clinical research in oncology; integrated solutions, research, development of processes and services in genomics; and laboratory analysis services. In add...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1926
• Employees: 29,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: FLRY3

Financial Performance

In 2025, Fleury's revenue was 8.29 billion, an increase of 7.89% compared to the previous year's 7.68 billion. Earnings were 612.83 million, a decrease of -0.54%.

Analyst Summary

According to 11 analysts, the average rating for FLRY3 stock is "Buy." The 12-month stock price target is R$17.50, which is an increase of 15.28% from the latest price.

Price Target

R$17.50

(15.28% upside)

Analyst Consensus: Buy